ReviewClinics in dermatology
COVID-19-related skin manifestations: Update on therapy.
Review in Clinics in dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Fibroblast-derived small extracellular vesicles loaded with tacrolimus enhances dermal delivery and alleviates cytokine-overdriven skin inflammation.Drug delivery and translational research · 2026Article
- Acne care in health care providers during the COVID-19 pandemic: A national survey.Dermatologic therapy · 2022Article
- Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management.Viruses · 2022Review
- Dermatology and COVID-19: The Hidden Pandemic.Journal of clinical medicine · 2022Article
- Article
- The clot thickens with COVID-19 and cryofibrinogenemia: A thought-provoking association.JAAD case reports · 2022Article
- COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?International journal of molecular sciences · 2022Review
- Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.Journal of medical virology · 2021Review
- Review
- Defining the short-term and long-term skin manifestations of COVID-19: insights after more than three years of the pandemic.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing body of evidence has been produced in a very limited period to improve the understanding of skin involvement in the current coronavirus 2019 disease pandemic, and how this novel disease affects the management of dermatologic patients. A little explored area is represented by the therapeutic approach adopted for the different skin manifestations associated with the infection. An overview of the current scenario is provided, through review of the English-language literature published until October 30, 2020, and comparison with the personal experience of the authors. As dermatologists, our primary aim is to support patients with the highest standard of care and relieve suffering, even with lesions not life-threatening. With asymptomatic COVID-19 patients, patient discomfort related to skin lesions should not be undervalued and intervention to accelerate healing should be provided. Consensus protocols are warranted to assess the best skin-targeted treatments in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.